The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer

Epithelial ovarian cancer (EOC) is treated in the first-line setting with combined platinum and taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase inhibitor (PARPi). Responses to first-line treatment are frequent. For many patients, however, responses are suboptimal or...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouberhan, Sara, Bar-Peled, Liron, Matoba, Yusuke, Mazina, Varvara, Philp, Lauren, Rueda, Bo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344720/
https://www.ncbi.nlm.nih.gov/pubmed/37457127
http://dx.doi.org/10.20517/cdr.2022.146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344720/
https://www.ncbi.nlm.nih.gov/pubmed/37457127
http://dx.doi.org/10.20517/cdr.2022.146

Ejemplares similares